

Disruption of KMT2D perturbs germinal center B cell development and lymphomagenesis

Nature Medicine

21, 1190-1198

DOI: [10.1038/nm.3940](https://doi.org/10.1038/nm.3940)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The routes for transformation of follicular lymphoma. <i>Current Opinion in Hematology</i> , 2016, 23, 385-391.	1.2	16
2	Recurrent giant cell fibroblastoma: Malignancy predisposition in Kabuki syndrome revisited. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 1333-1338.	0.7	17
3	The many layers of epigenetic dysfunction in B-cell lymphomas. <i>Current Opinion in Hematology</i> , 2016, 23, 377-384.	1.2	35
4	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. <i>Blood</i> , 2016, 128, 1101-1111.	0.6	115
5	Epigenetics of hematopoiesis and hematological malignancies. <i>Genes and Development</i> , 2016, 30, 2021-2041.	2.7	125
6	Chronic lymphocytic leukemia: Time to go past genomics?. <i>American Journal of Hematology</i> , 2016, 91, 518-528.	2.0	13
7	Enhancer deregulation in cancer and other diseases. <i>BioEssays</i> , 2016, 38, 1003-1015.	1.2	79
8	Dpy30 is critical for maintaining the identity and function of adult hematopoietic stem cells. <i>Journal of Experimental Medicine</i> , 2016, 213, 2349-2364.	4.2	48
9	MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026427.	2.9	122
10	Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2016, 76, 4861-4871.	0.4	72
11	ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions. <i>Epigenomics</i> , 2016, 8, 1239-1258.	1.0	22
12	A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. <i>Modern Pathology</i> , 2016, 29, 1212-1220.	2.9	46
13	Epigenetic balance of gene expression by Polycomb and COMPASS families. <i>Science</i> , 2016, 352, aad9780.	6.0	407
14	New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015â€“December 2015. <i>Journal of Hematopathology</i> , 2016, 9, 19-27.	0.2	3
15	The genetic evolution of skin squamous cell carcinoma: tumor suppressor identity matters. <i>Experimental Dermatology</i> , 2016, 25, 863-864.	1.4	6
16	KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation. <i>Development (Cambridge)</i> , 2016, 143, 810-821.	1.2	100
17	Catalog of genetic progression of human cancers: non-Hodgkin lymphoma. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 109-127.	2.7	7
18	The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies. <i>Expert Review of Hematology</i> , 2016, 9, 255-269.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma. <i>Oral Oncology</i> , 2017, 66, 38-45.	0.8	11
20	Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. <i>Epigenetics</i> , 2017, 12, 370-377.	1.3	31
21	Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2 : CALGB 151111 (Alliance). <i>Journal of Thoracic Oncology</i> , 2017, 12, 704-713.	0.5	71
22	Targeting HDAC3 in CREBBP-Mutant Lymphomas Counterstrikes Unopposed Enhancer Deacetylation of B-cell Signaling and Immune Response Genes. <i>Cancer Discovery</i> , 2017, 7, 14-16.	7.7	7
23	The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 322-337.	7.7	181
24	Murine models of germinal center derived-lymphomas. <i>Current Opinion in Immunology</i> , 2017, 45, 31-36.	2.4	18
25	Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. <i>Leukemia</i> , 2017, 31, 1243-1246.	3.3	33
26	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	1.7	39
27	Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001719.	0.5	22
28	Epigenetics in normal and malignant hematopoiesis: An overview and update 2017. <i>Cancer Science</i> , 2017, 108, 553-562.	1.7	44
29	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017, 8, 15429.	5.8	55
30	Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. <i>Journal of Internal Medicine</i> , 2017, 282, 371-394.	2.7	59
31	Follicular lymphoma: State of the Art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017, 35, 397-407.	0.8	11
32	PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. <i>Science</i> , 2017, 355, 1324-1330.	6.0	217
33	Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis. <i>Current Opinion in Hematology</i> , 2017, 24, 322-328.	1.2	39
34	Multiple Roles for the MLL/COMPASS Family in the Epigenetic Regulation of Gene Expression and in Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 425-446.	2.3	36
35	Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. <i>Blood</i> , 2017, 129, 280-288.	0.6	125
36	H3K4 Methyltransferase Activity Is Required for MLL4 Protein Stability. <i>Journal of Molecular Biology</i> , 2017, 429, 2046-2054.	2.0	47

#	ARTICLE	IF	CITATIONS
37	Drug Discovery and Chemical Biology of Cancer Epigenetics. <i>Cell Chemical Biology</i> , 2017, 24, 1120-1147.	2.5	47
38	PTIP chromatin regulator controls development and activation of B cell subsets to license humoral immunity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9328-E9337.	3.3	12
39	EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2586-2597.	1.9	57
40	Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. <i>Nature Cell Biology</i> , 2017, 19, 1093-1104.	4.6	58
41	Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 9701-9706.	3.3	97
42	Epigenetic plasticity and the hallmarks of cancer. <i>Science</i> , 2017, 357, .	6.0	920
43	The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. <i>Blood</i> , 2017, 130, 1491-1498.	0.6	29
44	Beyond genomics – Targeting the epigenome in diffuse large B-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2017, 59, 132-137.	3.4	5
45	Patients with a Kabuki syndrome phenotype demonstrate DNA methylation abnormalities. <i>European Journal of Human Genetics</i> , 2017, 25, 1335-1344.	1.4	52
46	Histone H3 lysine 4 methyltransferase KMT2D. <i>Gene</i> , 2017, 627, 337-342.	1.0	201
47	Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	52
48	Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. <i>Carcinogenesis</i> , 2017, 38, 2-11.	1.3	135
49	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , 2017, 7, 38-53.	7.7	218
50	SET/MLL family proteins in hematopoiesis and leukemia. <i>International Journal of Hematology</i> , 2017, 105, 7-16.	0.7	42
51	Indications to Epigenetic Dysfunction in the Pathogenesis of Common Variable Immunodeficiency. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 101-110.	1.0	23
52	Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas. <i>American Journal of Hematology</i> , 2017, 92, 68-76.	2.0	8
53	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in <i>TNFAIP3</i> followed by mutations in <i>TBL1XR1</i> and <i>CREBBP</i> . <i>Oncotarget</i> , 2017, 8, 17038-17049.	0.8	55
54	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 203-214.	1.2	58

#	ARTICLE	IF	CITATIONS
55	Genetics of diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2307-2319.	0.6	186
56	Critical influences on the pathogenesis of follicular lymphoma. <i>Blood</i> , 2018, 131, 2297-2306.	0.6	48
57	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. <i>Leukemia</i> , 2018, 32, 1261-1265.	3.3	87
58	An Mll4/COMPASS-Lsd1 epigenetic axis governs enhancer function and pluripotency transition in embryonic stem cells. <i>Science Advances</i> , 2018, 4, eaap8747.	4.7	55
59	KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis. <i>Genes and Development</i> , 2018, 32, 181-193.	2.7	77
60	From genetics to the clinic: a translational perspective on follicular lymphoma. <i>Nature Reviews Cancer</i> , 2018, 18, 224-239.	12.8	108
61	Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. <i>Oncogene</i> , 2018, 37, 1354-1368.	2.6	101
62	Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. <i>Haematologica</i> , 2018, 103, 679-687.	1.7	67
63	Frequent somatic mutations of <i>KMT2D</i> (<i>MLL2</i>) and <i>CARD11</i> genes in primary cold agglutinin disease. <i>British Journal of Haematology</i> , 2018, 183, 838-842.	1.2	53
64	High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1025-1035.	1.2	32
65	Chromatin modifying gene mutations in follicular lymphoma. <i>Blood</i> , 2018, 131, 595-604.	0.6	102
66	Novel epigenetic therapies in hematological malignancies: Current status and beyond. <i>Seminars in Cancer Biology</i> , 2018, 51, 198-210.	4.3	22
67	Methyltransferase Nsd2 Ensures Germinal Center Selection by Promoting Adhesive Interactions between B Cells and Follicular Dendritic Cells. <i>Cell Reports</i> , 2018, 25, 3393-3404.e6.	2.9	13
68	Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies. <i>Frontiers in Oncology</i> , 2018, 8, 556.	1.3	67
69	The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies. <i>Frontiers in Oncology</i> , 2018, 8, 550.	1.3	52
70	HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. <i>Cancer Cell</i> , 2018, 34, 643-658.e5.	7.7	94
71	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2018, 8, 1632-1653.	7.7	120
72	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs. <i>Seminars in Oncology</i> , 2018, 45, 291-302.	0.8	37

#	ARTICLE	IF	CITATIONS
73	Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 129-136.	1.0	31
74	STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2018, 9, 3696.	5.8	43
75	Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy. <i>Nature Medicine</i> , 2018, 24, 758-769.	15.2	125
76	MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes. <i>Molecular Cell</i> , 2018, 70, 825-841.e6.	4.5	123
77	Dissecting KMT2D missense mutations in Kabuki syndrome patients. <i>Human Molecular Genetics</i> , 2018, 27, 3651-3668.	1.4	49
78	KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. <i>Nature Communications</i> , 2018, 9, 2496.	5.8	39
79	Disrupting the Code: Epigenetic Dysregulation of Lymphocyte Function during Infectious Disease and Lymphoma Development. <i>Journal of Immunology</i> , 2018, 201, 1109-1118.	0.4	17
80	Enhancer Logic and Mechanics in Development and Disease. <i>Trends in Cell Biology</i> , 2018, 28, 608-630.	3.6	146
81	Proteomic profiling identifies key coactivators utilized by mutant ER α proteins as potential new therapeutic targets. <i>Oncogene</i> , 2018, 37, 4581-4598.	2.6	51
82	Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. <i>Nature Immunology</i> , 2018, 19, 1013-1024.	7.0	115
83	Frequent Mutations in Natural Killer/T Cell Lymphoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 1-16.	1.1	29
84	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. <i>Blood</i> , 2018, 132, 1695-1702.	0.6	49
85	Pathogenic B α cell receptor signaling in lymphoid malignancies: New insights to improve treatment. <i>Immunological Reviews</i> , 2019, 291, 190-213.	2.8	91
86	The Unexpected Noncatalytic Roles of Histone Modifiers in Development and Disease. <i>Trends in Genetics</i> , 2019, 35, 645-657.	2.9	29
87	Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells. <i>Frontiers in Oncology</i> , 2019, 9, 568.	1.3	7
88	Genetic mechanisms regulating the host response during mastitis. <i>Journal of Dairy Science</i> , 2019, 102, 9043-9059.	1.4	32
89	EP300 as an oncogene correlates with poor prognosis in esophageal squamous carcinoma. <i>Journal of Cancer</i> , 2019, 10, 5413-5426.	1.2	27
90	Epigenetic Programming of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 272.	1.8	34

#	ARTICLE	IF	CITATIONS
91	Chromatin-Remodeled State in Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 439-450.	1.2	4
92	Regulatory mechanisms of B cell responses and the implication in B cell-related diseases. <i>Journal of Biomedical Science</i> , 2019, 26, 64.	2.6	36
93	Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. <i>Immunity</i> , 2019, 51, 535-547.e9.	6.6	93
94	Genetic modification of primary human B cells to model high-grade lymphoma. <i>Nature Communications</i> , 2019, 10, 4543.	5.8	36
95	Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach. <i>Current Oncology Reports</i> , 2019, 21, 63.	1.8	6
96	Genetic alterations and their clinical implications in DLBCL. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 634-652.	12.5	136
97	Pharmacoeugenetics of Immunological Disorders. , 2019, , 573-586.		0
98	COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer. <i>Cancer Letters</i> , 2019, 458, 56-65.	3.2	121
99	KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108924.	2.5	24
100	Pathogenesis of B-Cell Lymphoma. , 2019, , 33-50.		0
101	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. <i>PLoS ONE</i> , 2019, 14, e0209134.	1.1	16
102	Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 7-15.	2.0	19
103	HVEM network signaling in cancer. <i>Advances in Cancer Research</i> , 2019, 142, 145-186.	1.9	30
104	Emerging epigenetic-modulating therapies in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 494-507.	12.5	80
105	Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. <i>Theranostics</i> , 2019, 9, 540-553.	4.6	49
106	Impact of B cell/lymphoid stromal cell crosstalk in B-cell physiology and malignancy. <i>Immunology Letters</i> , 2019, 215, 12-18.	1.1	14
107	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 2416-2428.	3.3	25
108	A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma. <i>Haematologica</i> , 2019, 104, e406-e409.	1.7	11

#	ARTICLE	IF	CITATIONS
109	Epigenetic regulation of B cell fate and function during an immune response. <i>Immunological Reviews</i> , 2019, 288, 75-84.	2.8	28
110	Molecular pathogenesis of germinal center-derived B cell lymphomas. <i>Immunological Reviews</i> , 2019, 288, 240-261.	2.8	53
111	Germinal center-derived lymphomas: The darkest side of humoral immunity. <i>Immunological Reviews</i> , 2019, 288, 214-239.	2.8	113
112	PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. <i>Cell Reports</i> , 2019, 27, 294-306.e5.	2.9	49
113	UTX Mutations in Human Cancer. <i>Cancer Cell</i> , 2019, 35, 168-176.	7.7	113
114	DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns. <i>Cancer Cell</i> , 2019, 35, 297-314.e8.	7.7	62
115	Follicular lymphoma: Biology update. <i>Hematologie</i> , 2019, 25, 23-31.	0.0	0
116	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. <i>Blood Advances</i> , 2019, 3, 3360-3374.	2.5	25
117	Follicular lymphoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 83.	18.1	148
118	Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel <i>KMT2D</i> mutation. <i>American Journal of Medical Genetics, Part A</i> , 2019, 179, 113-117.	0.7	10
119	A comparative analysis of <i>KMT2D</i> missense variants in Kabuki syndrome, cancers and the general population. <i>Journal of Human Genetics</i> , 2019, 64, 161-170.	1.1	26
120	Polycomb complexes in normal and malignant hematopoiesis. <i>Journal of Cell Biology</i> , 2019, 218, 55-69.	2.3	52
121	Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming. <i>Gut</i> , 2019, 68, 1271-1286.	6.1	53
122	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. <i>Nature Immunology</i> , 2019, 20, 86-96.	7.0	71
123	B cells turn on, tune in with LSD1. <i>Nature Immunology</i> , 2019, 20, 3-5.	7.0	7
124	G3BP1 enhances cytoplasmic DNA pattern recognition. <i>Nature Immunology</i> , 2019, 20, 5-7.	7.0	7
125	Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy. <i>Annual Review of Cancer Biology</i> , 2019, 3, 429-455.	2.3	18
126	Exome sequencing confirms diagnosis of kabuki syndrome in an-adult with hodgkin lymphoma and unusually severe multisystem phenotype. <i>Clinical Immunology</i> , 2019, 207, 55-57.	1.4	6

#	ARTICLE	IF	CITATIONS
127	Tumor-infiltrating lymphocyte-derived MLL2 independently predicts disease-free survival for patients with early-stage oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 126-136.	1.4	10
128	Abnormal Peyer patch development and B-cell gut homing drive IgA deficiency in Kabuki syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 982-992.	1.5	18
129	The histone methyltransferase KMT2D, mutated in Kabuki syndrome patients, is required for neural crest cell formation and migration. <i>Human Molecular Genetics</i> , 2020, 29, 305-319.	1.4	34
130	New murine models of aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 788-798.	0.6	4
131	Follicular Lymphoma. , 2020, , .		0
132	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. <i>Cell Reports</i> , 2020, 33, 108293.	2.9	39
133	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	5.1	306
134	Genetic and epigenetic determinants of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 123.	2.8	47
135	A small UTX stabilization domain of Trr is conserved within mammalian MLL3-4/COMPASS and is sufficient to rescue loss of viability in null animals. <i>Genes and Development</i> , 2020, 34, 1493-1502.	2.7	14
136	Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. <i>Clinical Epigenetics</i> , 2020, 12, 169.	1.8	40
137	The Biological Basis of Histologic Transformation. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 771-784.	0.9	4
138	Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies. <i>Genes</i> , 2020, 11, 846.	1.0	3
139	Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study. <i>Scientific Reports</i> , 2020, 10, 13359.	1.6	4
140	Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. <i>Clinical Epigenetics</i> , 2020, 12, 160.	1.8	23
141	Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1844-1855.	1.1	10
142	From Anti-EBV Immune Responses to the EBV Disease via Cross-reactivity. <i>Global Medical Genetics</i> , 2020, 07, 051-063.	0.4	12
143	Stem cell characteristics promote aggressiveness of diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2020, 10, 21342.	1.6	7
144	The Histone Methyltransferase DOT1L Is Essential for Humoral Immune Responses. <i>Cell Reports</i> , 2020, 33, 108504.	2.9	21

#	ARTICLE	IF	CITATIONS
145	MLL4-associated condensates counterbalance Polycomb-mediated nuclear mechanical stress in Kabuki syndrome. <i>Nature Genetics</i> , 2020, 52, 1397-1411.	9.4	53
146	Follicular lymphoma genomics. <i>Leukemia and Lymphoma</i> , 2020, 61, 2313-2323.	0.6	7
147	The MLL/SET family and haematopoiesis. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2020, 1863, 194579.	0.9	14
148	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. <i>Cancers</i> , 2020, 12, 1396.	1.7	42
149	Epigenetic mechanisms in the regulation of lymphocyte differentiation. , 2020, , 77-116.		3
150	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	7.1	66
151	Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591990085.	1.4	7
152	Primary CNS lymphoma commonly expresses immune response biomarkers. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa018.	0.4	24
153	Drug Resistance in Non-Hodgkin Lymphomas. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2081.	1.8	37
154	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2886-2898.	2.5	59
155	Generation of a Murine Model for c-MYC and BCL2 Co-expression B Cell Lymphomas. <i>Frontiers in Oncology</i> , 2020, 10, 1007.	1.3	2
156	Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 1267-1281.	7.7	40
157	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. <i>Nature Cancer</i> , 2020, 1, 653-664.	5.7	35
158	Generation and characterization of the E μ -Irf8 mouse model. <i>Cancer Genetics</i> , 2020, 245, 6-16.	0.2	5
159	Immunomodulatory Agents in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 715-726.	0.9	2
160	Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. <i>Journal of Clinical Pathology</i> , 2020, 73, 571-577.	1.0	7
161	IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4320-4327.	3.3	55
162	Comparative analysis of lung and blood transcriptomes in mice exposed to multi-walled carbon nanotubes. <i>Toxicology and Applied Pharmacology</i> , 2020, 390, 114898.	1.3	12

#	ARTICLE	IF	CITATIONS
163	FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells. <i>Cancer Research</i> , 2020, 80, 2498-2511.	0.4	19
164	KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. <i>Cancer Cell</i> , 2020, 37, 599-617.e7.	7.7	137
165	Comprehensive analysis of circRNA expression profiles and circRNA-associated competing endogenous RNA networks in the development of mouse thymus. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6340-6349.	1.6	3
166	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034959.	2.9	14
167	Mouse Models in the Study of Mature B-Cell Malignancies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a034827.	2.9	3
168	Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. <i>Blood</i> , 2021, 137, 2347-2359.	0.6	31
169	The Role of Epigenetic Mechanisms in B Cell Lymphoma Pathogenesis. <i>Annual Review of Cancer Biology</i> , 2021, 5, 311-330.	2.3	3
170	Diagnosis and treatment of lymphomas in the era of epigenetics. <i>Blood Reviews</i> , 2021, 48, 100782.	2.8	7
171	Comparison of gene mutation spectra in younger and older Chinese acute myeloid leukemia patients and its prognostic value. <i>Gene</i> , 2021, 770, 145344.	1.0	2
172	Germline variants of DNA repair genes in early onset mantle cell lymphoma. <i>Oncogene</i> , 2021, 40, 551-563.	2.6	9
173	Facial Dysmorphisms, Macrodontia, Focal Epilepsy, and Thinning of the Corpus Callosum: A Rare Mild Form of Kabuki Syndrome. <i>Journal of Pediatric Genetics</i> , 2021, 10, 049-052.	0.3	1
174	COMPASS and SWI/SNF complexes in development and disease. <i>Nature Reviews Genetics</i> , 2021, 22, 38-58.	7.7	142
175	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 922-933.	2.9	5
176	Decoding the role of coiled-coil motifs in human prion-like proteins. <i>Prion</i> , 2021, 15, 143-154.	0.9	5
177	Preventing phenotypic plasticity in cancer to mitigate therapy resistance. , 2021, , 119-160.		0
178	Follicular lymphoma dynamics. <i>Advances in Immunology</i> , 2021, 150, 43-103.	1.1	19
179	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 10.	7.1	93
180	Molecular Genetics in Indolent Lymphomas. <i>Hematologic Malignancies</i> , 2021, , 5-20.	0.2	0

#	ARTICLE	IF	CITATIONS
181	Histone methyltransferase DOT1L controls state-specific identity during B cell differentiation. <i>EMBO Reports</i> , 2021, 22, e51184.	2.0	27
182	The role of tazemetostat in relapsed/refractory follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110158.	1.1	11
183	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. <i>American Journal of Surgical Pathology</i> , 2021, 45, 905-916.	2.1	24
184	Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 641.	1.7	7
186	Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics. <i>Frontiers in Immunology</i> , 2021, 12, 597651.	2.2	9
187	KDM5 inhibition offers a novel therapeutic strategy for the treatment of <i>KMT2D</i> mutant lymphomas. <i>Blood</i> , 2021, 138, 370-381.	0.6	33
188	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 622648.	1.3	11
189	Novel targeted agents for follicular lymphoma. <i>Annals of Lymphoma</i> , 0, 5, 3-3.	4.5	1
190	Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation. <i>British Journal of Haematology</i> , 2021, 194, 810-821.	1.2	27
191	KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23721.	0.9	9
192	<i>miR-15a/16-1</i> deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. <i>Blood</i> , 2021, 137, 1905-1919.	0.6	8
193	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2022, 107, 690-701.	1.7	43
194	The language of chromatin modification in human cancers. <i>Nature Reviews Cancer</i> , 2021, 21, 413-430.	12.8	179
195	Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. <i>Nature Cancer</i> , 2021, 2, 515-526.	5.7	35
196	A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor. <i>International Journal of Surgical Pathology</i> , 2021, 29, 106689692110134.	0.4	0
197	Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy. <i>Hemato</i> , 2021, 2, 281-304.	0.2	1
198	Epigenetic gene regulation in plasma cells. <i>Immunological Reviews</i> , 2021, 303, 8-22.	2.8	10
199	What can clinical immunology learn from inborn errors of epigenetic regulators?. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1602-1618.	1.5	8

#	ARTICLE	IF	CITATIONS
200	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). <i>Current Cancer Drug Targets</i> , 2021, 21, 274-282.	0.8	10
201	Epigenetic balance in DLBCL. <i>Blood</i> , 2021, 138, 355-356.	0.6	2
202	Dynamic regulation of B cell complement signaling is integral to germinal center responses. <i>Nature Immunology</i> , 2021, 22, 757-768.	7.0	44
203	Genetic heterogeneity in follicular lymphoma. <i>Annals of Lymphoma</i> , 0, 5, 18-18.	4.5	4
204	Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. <i>Oncotarget</i> , 2021, 12, 1296-1308.	0.8	19
205	The Premalignant Ancestor Cell of t(14;18)+ Lymphoma. <i>HemaSphere</i> , 2021, 5, e579.	1.2	5
206	The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape. <i>Biochemical Society Transactions</i> , 2021, 49, 1041-1054.	1.6	29
207	Biology of Germinal Center B Cells Relating to Lymphomagenesis. <i>HemaSphere</i> , 2021, 5, e582.	1.2	11
208	Migration and Adhesion of B-Lymphocytes to Specific Microenvironments in Mantle Cell Lymphoma: Interplay between Signaling Pathways and the Epigenetic Landscape. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6247.	1.8	5
209	Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types. <i>Cancers</i> , 2021, 13, 3155.	1.7	14
210	An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach. <i>Cancers</i> , 2021, 13, 2893.	1.7	6
211	Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs. <i>PLoS Computational Biology</i> , 2021, 17, e1008408.	1.5	8
212	Genomic Analyses of Metaplastic or Sarcomatoid Carcinomas From Different Organs Revealed Frequent Mutations in KMT2D. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 688692.	1.6	4
213	CHARGE syndrome and related disorders: a mechanistic link. <i>Human Molecular Genetics</i> , 2021, 30, 2215-2224.	1.4	1
214	Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models. <i>Frontiers in Immunology</i> , 2021, 12, 683597.	2.2	6
215	Clinical heterogeneity of Kabuki syndrome in a cohort of Italian patients and review of the literature. <i>European Journal of Pediatrics</i> , 2022, 181, 171-187.	1.3	13
216	Loss of KMT2C reprograms the epigenomic landscape in hPSCs resulting in NODAL overexpression and a failure of hemogenic endothelium specification. <i>Epigenetics</i> , 2022, 17, 220-238.	1.3	7
217	Leveraging the Mendelian disorders of the epigenetic machinery to systematically map functional epigenetic variation. <i>ELife</i> , 2021, 10, .	2.8	10

#	ARTICLE	IF	CITATIONS
218	The unique biology of germinal center B cells. <i>Immunity</i> , 2021, 54, 1652-1664.	6.6	84
219	Mouse Models of Germinal Center Derived B-Cell Lymphomas. <i>Frontiers in Immunology</i> , 2021, 12, 710711.	2.2	6
220	Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes?. <i>British Journal of Haematology</i> , 2022, 196, 814-829.	1.2	51
221	Molecular Pathogenesis of Follicular Lymphoma and Its Relevance to Clinical Practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S175-S177.	0.2	0
223	A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia. <i>Acta Haematologica</i> , 2021, , 1-8.	0.7	1
224	Genetic features of B-cell lymphoblastic lymphoma with <i>TCF3</i> and <i>PBX1</i> . <i>Cancer Reports</i> , 2022, 5, e1559.	0.6	4
225	Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers. <i>EBioMedicine</i> , 2021, 71, 103559.	2.7	1
226	Enhancer-associated H3K4 methylation safeguards in vitro germline competence. <i>Nature Communications</i> , 2021, 12, 5771.	5.8	20
227	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncoimmunology</i> , 2021, 10, 1928365.	2.1	6
228	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. <i>Nature Immunology</i> , 2021, 22, 240-253.	7.0	24
229	Pathology and Molecular Pathogenesis of DLBCL and Related Entities. <i>Methods in Molecular Biology</i> , 2019, , 41-73.	0.4	2
230	Genomic Drivers in Follicular Lymphoma. , 2020, , 47-64.		2
236	An Autochthonous Mouse Model of <i>Myd88</i> - and <i>BCL2</i> -Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. <i>Blood Cancer Discovery</i> , 2021, 2, 70-91.	2.6	21
237	Precocious neuronal differentiation and disrupted oxygen responses in Kabuki syndrome. <i>JCI Insight</i> , 2019, 4, .	2.3	41
238	Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 3605-3618.	3.9	26
239	Follicular lymphoma-associated mutations in vacuolar ATPase <i>ATP6V1B2</i> activate autophagic flux and mTOR. <i>Journal of Clinical Investigation</i> , 2019, 129, 1626-1640.	3.9	23
240	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. <i>Blood</i> , 2020, 135, 360-370.	0.6	80
241	DEPENDENCE OF OVERALL AND RELAPSE-FREE PATIENTS SURVIVAL FROM MOLECULAR GENETIC SUBTYPE OF ESOPHAGEAL SQUAMOUS CELL CANCER. <i>Voprosy Onkologii</i> , 2019, 65, 691-700.	0.1	4

#	ARTICLE	IF	CITATIONS
242	One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. <i>Epigenomes</i> , 2021, 5, 22.	0.8	3
243	Targeting Gene Function in Germinal Center B Cells: A Practical Approach. <i>Methods in Molecular Biology</i> , 2017, 1623, 209-231.	0.4	0
244	Enhancer epigenomic regulation in differentiation, development and cancer. <i>FASEB Journal</i> , 2018, 32, 524.5.	0.2	0
250	Transformed Follicular Lymphoma. , 2020, , 135-163.		0
251	Zmiany genetyczne w chłoniaku rozlanym z dużymi komórkami B. <i>Acta Haematologica Polonica</i> , 2019, 50, 204-214.	0.1	1
253	KMT2D deficiency disturbs the proliferation and cell cycle activity of dental epithelial cell line (LS8) partially via Wnt signaling. <i>Bioscience Reports</i> , 2021, 41, .	1.1	8
254	Chromatin Immunoprecipitation Followed by Next-Generation Sequencing (ChIP-Seq) Analysis in Ewing Sarcoma. <i>Methods in Molecular Biology</i> , 2021, 2226, 265-284.	0.4	2
255	Using <i>Xenopus</i> to analyze neurocristopathies like Kabuki syndrome. <i>Genesis</i> , 2021, 59, e23404.	0.8	0
256	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. <i>Haematologica</i> , 2022, 107, 201-210.	1.7	12
261	The follicular lymphoma epigenome regulates its microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 21.	3.5	6
263	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 805195.	1.8	7
264	Genomic landscape of TCR β and TCR γ T-large granular lymphocyte leukemia. <i>Blood</i> , 2022, 139, 3058-3072.	0.6	24
265	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma. <i>Frontiers in Genetics</i> , 2022, 13, 826594.	1.1	6
266	Epigenetic Modifications in Lymphoma and Their Role in the Classification of Lymphomas. <i>Hemato</i> , 2022, 3, 174-187.	0.2	0
267	The Biology of Ocular Adnexal Marginal Zone Lymphomas. <i>Cancers</i> , 2022, 14, 1264.	1.7	3
268	Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY. <i>Scientific Reports</i> , 2022, 12, 5120.	1.6	4
269	Fbw7 Inhibits the Progression of Activated B-Cell Like Diffuse Large B-Cell Lymphoma by Targeting the Positive Feedback Loop of the LDHA/lactate/miR-223 Axis. <i>Frontiers in Oncology</i> , 2022, 12, 842356.	1.3	4
270	Krüppel-like factor 2 controls IgA plasma cell compartmentalization and IgA responses. <i>Mucosal Immunology</i> , 2022, 15, 668-682.	2.7	5

#	ARTICLE	IF	CITATIONS
271	Altered pathways and targeted therapy in double hit lymphoma. <i>Journal of Hematology and Oncology</i> , 2022, 15, 26.	6.9	13
272	The Status and Prospects of Epigenetics in the Treatment of Lymphoma. <i>Frontiers in Oncology</i> , 2022, 12, 874645.	1.3	7
273	Inhibition of H3K27me3 Demethylases Promotes Plasmablast Formation. <i>ImmunoHorizons</i> , 2021, 5, 918-930.	0.8	2
274	The molecular ontogeny of follicular lymphoma: gene mutations succeeding the <i>BCL2</i> translocation define common precursor cells. <i>British Journal of Haematology</i> , 2022, 196, 1381-1387.	1.2	5
275	Dynamic Change of Soluble Interleukin-2 Receptor Distinguished Diffuse Large B-Cell Lymphoma with Prognostic Significance and Tumor Microenvironment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
276	SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2022, 12, 1782-1803.	7.7	14
277	MLL1 inhibition reduces IgM levels in Waldenström macroglobulinemia. <i>Leukemia Research</i> , 2022, 116, 106841.	0.4	2
292	Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes. <i>Oncotarget</i> , 2022, 13, 677-683.	0.8	3
293	Metabolic control of epigenetic rearrangements in B cell pathophysiology. <i>Open Biology</i> , 2022, 12, 220038.	1.5	1
294	The epigenetic regulation of the germinal center response. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2022, 1865, 194828.	0.9	3
296	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. <i>Lab Animal</i> , 2022, 51, 191-202.	0.2	6
297	Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancer. <i>Translational Cancer Research</i> , 2022, 11, 2607-2621.	0.4	2
298	Aberrant SPOP-CHAF1A ubiquitination axis triggers tumor autophagy that endows a therapeutical vulnerability in diffuse large B cell lymphoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	2
299	Molecular characterization of an embryonal rhabdomyosarcoma occurring in a patient with Kabuki syndrome: report and literature review in the light of tumor predisposition syndromes. <i>Familial Cancer</i> , 2023, 22, 103-118.	0.9	2
300	Lpt, trr, and Hcf regulate histone mono- and dimethylation that are essential for <i>Drosophila</i> heart development. <i>Developmental Biology</i> , 2022, 490, 53-65.	0.9	4
301	The engagement of histone lysine methyltransferases with nucleosomes: structural basis, regulatory mechanisms, and therapeutic implications. <i>Protein and Cell</i> , 0, , .	4.8	1
302	Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. <i>Nature</i> , 2022, 607, 808-815.	13.7	55
303	A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7

#	ARTICLE	IF	CITATIONS
305	Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	4
306	Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
307	A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 99-106.	1.2	2
308	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
309	Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group. <i>Cancer Genetics</i> , 2022, 268-269, 1-21.	0.2	0
310	Overexpression of interleukin-20 correlates with favourable prognosis in diffuse large B-cell lymphoma. <i>Pathology</i> , 2022, , .	0.3	1
311	The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. <i>Journal of the National Cancer Center</i> , 2022, 2, 277-290.	3.0	16
312	Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice. <i>Hemato</i> , 2022, 3, 595-614.	0.2	4
313	Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment. <i>Journal of Investigative Dermatology</i> , 2023, 143, 189-196.	0.3	2
314	Identification of unique DNA methylation sites in Kabuki syndrome using whole genome bisulfite sequencing and targeted hybridization capture followed by enzymatic methylation sequencing. <i>Journal of Human Genetics</i> , 0, , .	1.1	1
315	Systemic Presentation of Somatic <i>TET2</i> Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline <i>KMT2D</i> Variant. <i>American Journal of Clinical Pathology</i> , 0, , .	0.4	0
317	Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis. <i>Pathology</i> , 2022, , .	0.3	0
318	BCORL1 S878G, GNB1 G116S, SH2B3 A536T, and KMT2D S3708R tetramutation co-contribute to a pediatric acute myeloid leukemia: Case report and literature review. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	0
319	Biological and clinical significance of epigenetic alterations in B-cell lymphomas. <i>International Journal of Hematology</i> , 2022, 116, 821-827.	0.7	1
320	Epigenetic factor competition reshapes the EMT landscape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	5
322	Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	14
323	Distinct Genetically Determined Origins of <i>Myd88</i> / <i>BCL2</i> -Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies. <i>Blood Cancer Discovery</i> , 2023, 4, 78-97.	2.6	4
324	Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by <i>CEBP</i> / <i>IGH</i> fusion gene. <i>Cancer Science</i> , 2023, 114, 781-792.	1.7	3

#	ARTICLE	IF	CITATIONS
325	KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. <i>Cancer Cell</i> , 2023, 41, 88-105.e8.	7.7	12
326	Characterizing crosstalk in epigenetic signaling to understand disease physiology. <i>Biochemical Journal</i> , 2023, 480, 57-85.	1.7	4
327	A fast lasso-based method for inferring higher-order interactions. <i>PLoS Computational Biology</i> , 2022, 18, e1010730.	1.5	1
328	The Immunology of DLBCL. <i>Cancers</i> , 2023, 15, 835.	1.7	10
329	Molecular classification and therapeutics in diffuse large B-cell lymphoma. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	0
330	Advances in the multi-omics landscape of follicular lymphoma. <i>International Journal of Biological Sciences</i> , 2023, 19, 1955-1967.	2.6	0
332	Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	20
333	KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	5
334	Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors. <i>Cancer Discovery</i> , 2023, 13, 1310-1323.	7.7	9
335	Characterizing the molecular impact of <i>KMT2D</i> variants on the epigenetic and transcriptional landscapes in kabuki syndrome. <i>Human Molecular Genetics</i> , 0, , .	1.4	1
347	Epigenetic alterations and advancement of lymphoma treatment. <i>Annals of Hematology</i> , 0, , .	0.8	1
349	Context-Dependent Functions of KDM6 Lysine Demethylases in Physiology and Disease. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 139-165.	0.8	0
350	Alterations of histone modifications in cancer. , 2024, , 85-172.		0
354	Anti-CD20 antibody treatment for B-cell malignancies. , 2024, , 31-75.		0
359	Tumor-suppressive functions of protein lysine methyltransferases. <i>Experimental and Molecular Medicine</i> , 2023, 55, 2475-2497.	3.2	0
366	Molekulargenetik bei indolenten Lymphomen. , 2023, , 5-22.		0
367	Roles and Regulation of H3K4 Methylation During Mammalian Early Embryogenesis and Embryonic Stem Cell Differentiation. <i>Advances in Experimental Medicine and Biology</i> , 2024, , .	0.8	0
370	Molecular Pathogenesis of B-Cell Lymphomas. , 2024, , 309-333.		0

#	ARTICLE	IF	CITATIONS
371	Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma. Blood Cancer Journal, 2024, 14, .	2.8	0